Welcome Message
Towards the 51st Annual Meeting of the Japanese Society of Myeloma
51st Annual Meeting of the Japanese Society of Myeloma
President Hirohiko Shibayama
Department of Hematology, National Hospital Organization Osaka National Hospital
Conference Theme: "20 Years of Learning from the Past to Create the Future"
We are pleased to announce that the Annual Meeting of the Japanese Society of Myeloma will be held in Osaka for the first time in May 2026.
The year 2026 marks exactly 20 years since the approval of Velcade, a proteasome inhibitor and new treatment drug for multiple myeloma, in Japan in 2006. Following Velcade, immunomodulatory drugs and antibody drugs have been developed. Furthermore, with the emergence of CAR-T cell therapy, bispecific antibodies, and ADCs, the treatment outcomes for multiple myeloma have improved dramatically. Not only in terms of treatment drugs, but we have also seen remarkable progress in diagnostic technologies such as genetic diagnosis and MRD measurement.
We aim to create a conference where we can reflect on these 20 years and discuss how to best utilize these treatment drugs and diagnostic technologies to provide satisfactory treatment for multiple myeloma patients.
The venue will be located within the newly constructed Grand Green Osaka on the north side of JR Osaka Station. We invite you to learn about multiple myeloma while also enjoying Osaka's new landmark.